A 26-week Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Effect of Omalizumab on Markers of Impairment in Patients with Persistent Allergic Asthma
Description of Research
Evaluate the effect of omalizumab on markers of impairment as measured by the Asthma Control Test (ACT) scores at 24 weeks of treatment, in patients with inadequately controlled persistent allergic asthma.
Study Number
HSR-09-1013
Inclusion/Notes
Male or female patients 12 years of age or older with inadequately controlled persistent allergic asthma who fulfill other study criteria.
